Erratum: Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome (J Bone Miner Metab, 10.1007/s00774-010-0211-2);Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome

Journal of Bone and Mineral Metabolism

Volumn 29, Issue 2, 2011, Pages 201-206

  Diamanti Kandarakis, Evanthia ^a   Livadas, Sarantis ^a   Katsikis, Ilias ^b   Piperi, Christine ^a   Aimilia, Mantziou ^a   Papavassiliou, Athanasios G ^a   Panidis, Dimitrios ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Androgens; Osteoblast; Osteocalcin; Polycystic ovarian syndrome

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANDROGEN; BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN;

ADULT; ARTICLE; BODY MASS; CARBOXYLATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; OBESITY; ORGAN SIZE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY; UPREGULATION; WAIST HIP RATIO;

EID: 79960024551     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-010-0238-4     Document Type: Erratum

References (22)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocr Metab 84:4006-4011 (Pubitemid 30644187)
2. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG (2005) Beta-cell function: a key pathological determinant in polycystic ovary syndrome. J Clin Endocrinol Metab 90:310-315 (Pubitemid 40116673)
3. Lee NK, Karsenty G (2008) Reciprocal regulation of bone and energy metabolism. Trends Endocr Metab 19:161-166 (Pubitemid 351847838)
4. Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates beta-cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105:5266-5270 (Pubitemid 351738545)
5. Cassese A, Esposito I, Fiory F, Barbagallo AP, Paturzo F, Mirra P, Ulianich L, Giacco F, Iadicicco C, Lombardi A, Oriente F, Van Obberghen E, Beguinot F, Formisano P, Miele C (2008) In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs. J Biol Chem 283:36088-36099
6. Franke S, Siggelkow H, Wolf G, Hein G (2007) Advanced glycation end products influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Phys Biochem 113:154-161 (Pubitemid 47547388)
7. Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papasotiriou I (2008) Low free plasma levels of retinol-binding protein 4 in insulin-resistant subjects with polycystic ovary syndrome. J Endocrinol Invest 31:950-954
8. Panidis D, Balaris C, Farmakiotis D, Rousso D, Kourtis A, Balaris V, Katsikis I, Zournatzi V, Diamanti-Kandarakis E (2005) Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem 51:1691-1697 (Pubitemid 41233105)
9. Diamanti-Kandarakis E, Piouka A, Livadas S, Piperi C, Katsikis I, Papavassiliou AG, Panidis D (2008) Antimullerian hormone is associated with advanced glycosylated end products in women with polycystic ovary syndrome. Eur J Endocr 158:525-531
10. Young MF (2003) Bone matrix proteins: their function, regulation, and relationship to osteoporosis. Osteoporos Int 14:S35-S42
11. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469 (Pubitemid 47208519)
12. Horiuchi T, Kazama H, Araki A, Inoue J, Hosoi T, Onouchi T, Mizuno S, Ito H, Orimo H (2004) Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density. J Bone Miner Metab 22:236-240 (Pubitemid 38660954)
13. Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, Smith U, Mellström D (2009) Plasma osteocalcin is inversely related to fat mass and glucose in elderly Swedish men. J Bone Miner Res 24:785-791
14. Im JA, Yu BP, Jeon JY, Kim SH (2008) Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta 396:66-69
15. Hwang YC, Jeong IK, Kyu JA, Chung HO (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced b-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25:768-772
16. Shea MK, Gundberg CM, Meigs JB, Dallal GE, Saltzman E, Yoshida M, Jacques PF, Booth SL (2009) c-Carboxylation of osteocalcin and insulin resistance in older men and women. Am J Clin Nutr 90:1230-1235
17. Kanazawa I, Yamaguchi T, Yamamoto M, Kurioka S, Yano S, Sugimoto T (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocr Metab 94:45-49
18. Schurman L, McCarthy AD, Sedlinsky C, Gangoiti MV, Arnol V, Bruzzone L, Cortizo AM (2008) Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocr Diabetes 116:333-340 (Pubitemid 351947863)
19. Escobar-Morreale HF, Botella-Carretero JI, Martinez-Garcia MA, Luque-Ramírez M, Alvarez-Blasco F, San Millán JL (2008) Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. Eur J Endocrinol 159:225-232
20. Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P (1998) Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocr (Oxf) 48:169-173 (Pubitemid 28091047)
21. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP (2008) Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocr Metab 93:1696-1701 (Pubitemid 351656507)
22. Vega D, Maalouf NM, Sakhaee K (2007) Clinical review #: the role of receptor activator of nuclear factor-kappaB (RANK)/ RANK ligand/osteoprotegerin: clinical implications. J Clin Endocr Metab 92:4514-4521 (Pubitemid 350223419)